| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6407079 | JAVELIN PHARMS INC | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
Jun, 2019
(4 years ago) | |
| US8946292 | JAVELIN PHARMS INC | Formulations of low dose diclofenac and beta-cyclodextrin |
Mar, 2027
(2 years from now) | |
Dyloject is owned by Javelin Pharms Inc.
Dyloject contains Diclofenac Sodium.
Dyloject has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Dyloject are:
- US6407079
Dyloject was authorised for market use on 23 December, 2014.
Dyloject is available in solution;intravenous dosage forms.
Dyloject can be used as management of pain.
The generics of Dyloject are possible to be released after 22 March, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 23, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Management of pain
Dosage: SOLUTION;INTRAVENOUS
How can I launch a generic of DYLOJECT before it's drug patent expiration?
More Information on Dosage
DYLOJECT family patents
